Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | SCN3A | Q9NY46 | 5/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phthalylsulfacetamide SCHEMBL3911720 | 0.99 | ALDH1A1 (0.65) | ALDH1A1MAPTPKMHTTLMNA | |
| SCHEMBL27450474 | 0.84 | HSD17B10 (0.71) | ALDH1A1MAPTPKMHTTLMNA | |
| Phthalylsulfacetamide SCHEMBL7836470 | 0.84 | ALDH1A1 (0.53) | ALDH1A1MAPTPKMHTTLMNA | |
| SCHEMBL6225889 | 0.84 | ALDH1A1 (0.78) | ALDH1A1MAPTPKMHTTSCN3A | |
| SCHEMBL14291632 | 0.82 | ALDH1A1 (0.76) | ALDH1A1MAPTLMNACYP3A4L3MBTL1 | |
| SCHEMBL14607436 | 0.82 | ALDH1A1 (0.59) | ALDH1A1MAPTPKMHTTLMNA | |
| Sulfaloxic Acid SCHEMBL151073 | 0.82 | LMNA (0.56) | ALDH1A1MAPTLMNACYP3A4PTGS1 | |
| SCHEMBL12189487 | 0.81 | ALDH1A1 (0.69) | ALDH1A1MAPTLMNACYP3A4PTGS1 | |
| SCHEMBL12700342 | 0.81 | ALDH1A1 (0.69) | ALDH1A1LMNACYP3A4PTGS1TDP1 | |
| SCHEMBL18132522 | 0.80 | ALDH1A1 (0.55) | ALDH1A1MAPTLMNACYP3A4PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1783 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3829310-B1 | AGROCHEMICAL COMPOSITION AND METHODS OF PREPARING AND USING THE SAME | SPECIALTY OPERATIONS FRANCE (FR) | 2025-06-25 | — | — | EP | claimed |
| US-20250099557-A1 | ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION | SHANGHAI BAO PHARMACEUTICALS CO., LTD. (CN) | 2025-03-27 | — | — | US | claimed |
| WO-2025032301-A1 | METHOD FOR SPINNING AN ELASTIC YARN | DECATHLON (FR) | 2025-02-13 | — | — | WO | claimed |
| EP-4374848-A1 | ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION | Shanghai Bao Pharmaceuticals Co., Ltd. (CN) | 2024-05-29 | — | — | EP | claimed |
| US-20230346879-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-11-02 | — | — | US | claimed |
| EP-2252144-B1 | USE OF ESTER AMIDES AS SOLVENTS, ESTER AMIDES AS SUCH, AND METHOD FOR PREPARING ESTER AMIDES | RHODIA OPERATIONS (FR) | 2023-08-02 | — | — | EP | claimed |
| CN-113539369-B | Optimized kraken2 algorithm and application thereof in second-generation sequencing | 江苏先声医学诊断有限公司 | 2022-03-25 | — | — | CN | claimed |
| CN-113539369-A | Optimized kraken2 algorithm and application thereof in second-generation sequencing | 江苏先声医学诊断有限公司 | 2021-10-22 | — | — | CN | claimed |
| US-10449247-B2 | Compositions and methods for enhancing immune response | AVIVAGEN INC. (CA) | 2019-10-22 | — | — | US | claimed |
| EP-2953624-B1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | LUODA PHARMA LTD (IE) | 2019-08-21 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0786999-A4 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO INC (US) | 1999-01-20 | — | — | EP | claimed |
| EP-0792371-A4 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO INC (US) | 1998-12-30 | — | — | EP | claimed |
| EP-0792371-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-09-03 | — | — | EP | claimed |
| EP-0786999-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-08-06 | — | — | EP | claimed |
| EP-0741570-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1996-11-13 | — | — | EP | claimed |
| US-5543417-A | 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent | MERCK & CO., INC. (US) | 1996-08-06 | — | — | US | claimed |
| WO-1996012487-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1996012817-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1995020387-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1995-08-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346879-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | RAB5IF, CLTB, TBK1 | ALDH1A1 3381/4885MAPT 1926/4885PKM 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.